Bioelectronics Corp Revenue vs. Beta
| BIEL Stock | USD 0.0003 0.0001 50.00% |
For Bioelectronics Corp profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bioelectronics Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bioelectronics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bioelectronics Corp's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bioelectronics Corp over time as well as its relative position and ranking within its peers.
Bioelectronics |
Bioelectronics Corp Beta vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bioelectronics Corp's current stock value. Our valuation model uses many indicators to compare Bioelectronics Corp value to that of its competitors to determine the firm's financial worth. Bioelectronics Corp is rated fifth in revenue category among its peers. It is rated below average in beta category among its peers . The ratio of Revenue to Beta for Bioelectronics Corp is about 3,600,582 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bioelectronics Corp's earnings, one of the primary drivers of an investment's value.Bioelectronics Revenue vs. Competition
Bioelectronics Corp is rated fifth in revenue category among its peers. Market size based on revenue of Medical Devices industry is currently estimated at about 2.53 Billion. Bioelectronics Corp adds roughly 1.61 Million in revenue claiming only tiny portion of all equities under Medical Devices industry.
Bioelectronics Beta vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Bioelectronics Corp |
| = | 1.61 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Bioelectronics Corp |
| = | 0.45 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Bioelectronics Beta Comparison
Bioelectronics Corp is currently under evaluation in beta category among its peers.
Beta Analysis
As returns on the market increase, Bioelectronics Corp's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bioelectronics Corp is expected to be smaller as well.
Bioelectronics Corp Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bioelectronics Corp, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bioelectronics Corp will eventually generate negative long term returns. The profitability progress is the general direction of Bioelectronics Corp's change in net profit over the period of time. It can combine multiple indicators of Bioelectronics Corp, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. The company was incorporated in 2000 and is headquartered in Frederick, Maryland. BIOELECTRONICS CORP operates under Medical Devices classification in the United States and is traded on OTC Exchange.
Bioelectronics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bioelectronics Corp. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bioelectronics Corp position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bioelectronics Corp's important profitability drivers and their relationship over time.
Use Bioelectronics Corp in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bioelectronics Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bioelectronics Corp will appreciate offsetting losses from the drop in the long position's value.Bioelectronics Corp Pair Trading
Bioelectronics Corp Pair Trading Analysis
The ability to find closely correlated positions to Bioelectronics Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bioelectronics Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bioelectronics Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bioelectronics Corp to buy it.
The correlation of Bioelectronics Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bioelectronics Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bioelectronics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bioelectronics Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bioelectronics Corp position
In addition to having Bioelectronics Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bioelectronics Pink Sheet
To fully project Bioelectronics Corp's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bioelectronics Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bioelectronics Corp's income statement, its balance sheet, and the statement of cash flows.